English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Rituximab in the combination of CHOP chemotherapy has been widely used as the standard treatment for several kinds of B-cell non-Hodgkin lymphoma (B-NHL). Inactivation of phosphorylation of  STAT3  plays an essential role in rituximab-induced anti-proliferative activity in B-cell lymphoma. However, the relationship between  STAT3  genetic polymorphisms and clinical response to standard frontline treatment with rituximab has not been well illustrated yet.    Methods  In this study we analyzed the  STAT3  polymorphisms and prognosis of 166 diffuse large B-cell lymphoma (DLBCL) patients who were treated with rituximab from 2007 to 2010. Determination of the  STAT3  polymorphisms of rs2293152 from genomic DNA was achieved by Sanger chain termination sequencing.    Results  We did not observe obvious correlation between patients’ disease features and  STAT3  polymorphisms, but patients with homozygous genotypes at rs2293162 showed a trend of higher CR rate than those with the heterozygous genotype, especially in non-GCB subgroup ( p  = 0.011). Furthermore, homozygous genotypes GG and CC also showed advantages of long-term survival compared with heterozygous genotype patients ( p  = 0.022).    Conclusions  These results suggest that  STAT3  polymorphisms could be a suitable biomarker related to clinical outcome of DLBCL patients treated with rituximab.

Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab